TOXICOLOGICAL PROFILE FOR 1,1-DICHLOROETHENE

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

1,1-DICHLOROETHENE ii

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

1,1-DICHLOROETHENE

UPDATE STATEMENT

A Toxicological Profile for 1,1-dichloroethene was released on December 1990. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary, but no less than once every thret: years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry

Division of Toxicology/Toxicology Information Branch

1600 Clifton Road NE, E-29

Atlanta, Georgia 30333

FOREWORD

The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) extended and amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The revised list of the 275 most hazardous substances was published in the Federal Register on October 28, 1992 (57 FR 48801). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); and October 17, 1991 (56 FR 52166).

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. Each profile must include the following:

- (A) The examination, summary, and interpretation of available toxicological information and epidemiological evaluations on a hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects.
- (C) Where appropriate, identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the <u>Federal Register</u> on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile is intended to succinctly characterize the toxicological and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented, but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Each toxicological profile begins with a public health statement, that describes in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protect public health will be identified by ATSDR and EPA. The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document.

Foreword

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and Prevention (CDC), and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

David Satcher, M.D., Ph.D.

Administrator

Agency for Toxic Substances and Disease Registry

1,1-DICHLOROETHENE vii

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Cassandra Smith-Simon, M.S.
ATSDR, Division of Toxicology, Atlanta, GA

Sanjivani Diwan, Ph.D.

Clement International Corporation, Fairfax, VA

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

- 1. Green Border Review. Green Border review assures the consistency with ATSDR policy.
- 2. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying endpoints.
- 3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
- 4. Quality Assurance Reviews. The Quality Assurance Branch assures that consistency across profiles is maintained, identifies any significant problems in format or content, and establishes that Guidance has been followed.

1,1-DICHLOROETHENE ix

PEER REVIEW

A peer review panel was assembled for 1,1-dichloroethene. The panel consisted of the following members:

- Dr. C. Clifford Conaway, Research Scientist, American Health Foundation, Valhalla, New York
- 2. Dr. Arthur Gregory, Private Consultant, Techto Enterprises, Sterling, Virginia
- 3. Dr. Nancy Tooney, Associate Professor of Biochemistry, Department of Chemistry, Polytechnic University, Brooklyn, New York.

These experts collectively have knowledge of 1,1-dichloroethene's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREV	ORD	•••••	١
CONTR	IBUTORS .		νi
PEER I	REVIEW	•••••	iz
LIST O	F FIGURES		χī
LIST O	FTABLES .	XX	⁄i
1. PUB 1.1 1.2 1.3 1.4 1.5 1.6 1.7	WHAT IS 1, WHAT HAP ENVIRONM HOW MIGH HOW CAN HOW CAN IS THERE A EXPOSED TO WHAT REC	PENS TO 1,1-DICHLOROETHENE WHEN IT ENTERS THE IENT? IT I BE EXPOSED TO 1,1-DICHLOROETHENE? 1,1-DICHLOROETHENE ENTER AND LEAVE MY BODY? 1,1-DICHLOROETHENE AFFECT MY HEALTH? A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN TO 1,1-DICHLOROETHENE? COMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE CT HUMAN HEALTH?	2
2. HEA 2.1 2.2	INTRODUC DISCUSSIO 2.2.1 Inhala 2.2.1.2 2.2.1.3 2.2.1.4 2.2.1.5 2.2.1.6 2.2.1.7 2.2.1.8	Death 1 Systemic Effects 1 Immunological Effects 3 Neurological Effects 3 Reproductive Effects 3 Developmental Effects 3 Genotoxic Effects 3 Cancer 3 Exposure 3 Death 3 Systemic Effects 3	9 11 12 12 30 31 31 32 33 37
	2.2.2.4 2.2.2.5 2.2.2.6 2.2.2.7 2.2.2.8	Neurological Effects 4 Reproductive Effects 4 Developmental Effects 4 Genotoxic Effects 4 Cancer 4 Exposure 5	17 18 18 18

1,1-DICHLOROETHENE xii

		•	50 51
		•	51
		•	51
			51
			51
			51
	2.3	-	52
	2.5		53
			53
		•	53
		· · · · · · · · · · · · · · · · · · ·	55
		•	55
			55
		1	56
		•	56
		•	57
		<u>*</u>	57
			63
			63
		•	64
		k	66
		•	66
		•	66
	2.4		67
	2.5		83
			84
			85
	2.6	♥ · ·	86
	2.7		87
	2.8		90
			90
			90
			90
	2.9		91
			92
		· · · · · · · · · · · · · · · · · · ·	94
		2.9.3 On-going Studies	
			•
3.	CHE	EMICAL AND PHYSICAL INFORMATION 10	03
	3.1		03
	3.2	PHYSICAL AND CHEMICAL PROPERTIES	
4.	PRO	DUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	07
	4.1	PRODUCTION 10	
	4.2	IMPORT/EXPORT 10	09
	4.3	USE 10	
	4.4	DISPOSAL 10	09

1,1-DICHLOROETHENE xiii

5.	POT	ENTIAL FOR HUMAN EXPOSURE	1
	5.1	OVERVIEW	
	5.2	RELEASES TO THE ENVIRONMENT	4
		5.2.1 Air	4
		5.2.2 Water	15
		5.2.3 Soil	
	5.3	ENVIRONMENTAL FATE	
		5.3.1 Transport and Partitioning	
		5.3.2 Transformation and Degradation	
		5.3.2.1 Air	
		5.3.2.2 Water	18
		5.3.2.3 Sediment and Soil	9
	5.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 12	20
		5.4.1 Air	20
		5.4.2 Water	21
		5.4.3 Sediment and Soil	22
		5.4.4 Other Environmental Media	
	5.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	
	5.6	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 12	
	5.7	ADEQUACY OF THE DATABASE	
		5.7.1 Identification of Data Needs	
		5.7.2 On-going Studies	28
6.		ALYTICAL METHODS	
	6.1	BIOLOGICAL MATERIALS	
	6.3	ADEQUACY OF THE DATABASE	
		6.3.1 Identification of Data Needs	
		6.3.2 On-going Studies	39
_	n ma	NULL ACTIONS AND ADVISODITIS	
7.	REC	GULATIONS AND ADVISORIES	ŧΙ
o	DEE	TERENCES	15
ο.	KEF	ERENCES	IJ
a	GLC	DSSARY	71
7.	OLC	33AK1	/ 1
ΑI	PPFN	DICES	
4 XI			
	A. 1	USER'S GUIDE	-1
			-
	В. А	ACRONYMS, ABBREVIATIONS, AND SYMBOLS B.	-1

1,1-DICHLOROETHENE xv

LIST OF FIGURES

2-1	Levels of Significant Exposure to 1,1-Dichloroethene - Inhalation	20
2-2	Levels of Significant Exposure to 1,1-Dichloroethene - Oral	43
2-3	Percentage Systemic Uptake of 1,1-Dichloroethene During Inhalation Exposures	54
2-4	Metabolic Pathway for 1,1-Dichloroethene in Animals	58
2-5	Physiologically Based Pharmacokinetic Model for 1,1-Dichloroethene	59
2-6	General Proposed Scheme for Oxidative and Conjugative Metabolism of 1,1-Dichloroethene not Metabolized via the Epoxide Intermediate	61
2-7	Existing Information of Health Effects of 1,1-Dichloroethene	93
5-1	Frequency of NPL Sites with 1,1-Dichloroethene Contamination	113

		en e	

LIST OF TABLES

2 - I	Levels of Significant Exposure to 1,1-Dichloroethene - Innalation	13
2-2	Levels of Significant Exposure to 1,1-Dichloroethene - Oral	39
2-3	Genotoxicity of 1,1-Dichloroethene In Vitro	78
2-4	Genotoxicity of 1,1-Dichloroethene In Vivo	80
3-1	Chemical Identity of 1,1-Dichloroethene	104
3-2	Physical and Chemical Properties of 1,1-Dichloroethene	105
4-1	Facilities That Manufacture or Process 1,1-Dichloroethene	108
5-1	Releases to the Environment from Facilities That Manufacture or Process 1,1-Dichloroethene	112
6-1	Analytical Methods for Determining 1,1-Dichloroethene in Biological Materials	133
6-2	Analytical Methods for Determining 1,1-Dichloroethene in Environmental Samples	135
7-1	Regulations and Guidelines Applicable to 1,1-Dichloroethene	142